Heme complications of pregnancy Flashcards
Gestational thrombocytopenia features - 1) plt count 2) when it’s more common
Mild (100-150K) + more common as gestation progresses + no other CBC abnormalities + no increased bleeding or bruising
ITP in pregnancy clinical features
*Thrombocytopenia <100k in pregnancy without other CBC abnormalities is typically ITP
Most common cause of thrombocytopenia during 1st and 2nd/3rd trimesters
ITP in 1st
gestational thrombocytopenia in 2nd and 3rd
Goal platelet count for ITP in pregnancy for neuraxial anesthesia
Greater than 70k
First line treatment of ITP in pregnancy
- prednisone +/- IVIG
*pred preffered over dex since dex has placental transmission and can result in adverse effects to fetus
TTP management in pregnancy + role of rituximab and caplacizumab
PLEX
Steroids
*Use of rituximab has to be weighed against maternal and fetal risks
*Safety of caplacizumab is unknown so not advised
fetal & neonatal alloimmune thrombocytopenia clinical features
- neonate with severe thrombocytopenia and parents with no heme history
*this is analogous to hemolytic disease of the newborn for platelets (mother lacks HPA-1a antigen that father has, crosses placenta, and destroys fetus’s platelets)
Most common antibody in neonatal alloimmune thrombocytopenia
HPA-1a
Management of fetal neonatal alloimmune thrombocytopenia
- platelet transfusion if indicated (HPA-selected)
- cranial US to screen for ICH
Management of IDA in pregnancy during first trimester
oral iron
Ferritin threshold for anemia in pregnancy
<30
Peripartum management of LMWH (prophylactic and therapeutic)
Therapeutic lovenox:
Schedule delivery
Discontinue LMWH 24 hours prior
Prophylactic lovenox
Spontaneous labor
How long you need to hold LMWH for neuraxial anesthesia (therapeutic and prophylactic)
Need to hold therapeutic LMWH 24 hrs before, prophylactic LMWH 12 hours before
Indications for postpartum prophylaxis
- Unprovoked VTE
- estrogen-associated VTE
- ***VTE w/ a non-hormonal temporary risk factor (ASH doesn’t recommend antepartum prophylaxis)
Management of pregnant homozygous FVL patient
LMWH prophylaxis during pregnancy and postpartum